Home Ingredients Saberry® (Standardized Amla Extract — Sabinsa)
Metabolic HealthAntioxidant

Saberry® (Standardized Amla Extract — Sabinsa)

Phyllanthus emblica
Evidence Level
Strong
3 Clinical Trials
8 Documented Benefits
4/5 Evidence Score

Saberry® is Sabinsa's proprietary, patent-pending extract of fresh Indian Gooseberry fruit (Emblica officinalis / Phyllanthus emblica, commonly known as Amla) — the only Amla extract standardized to beta-glucogallin (a Gallotannin compound) as the key biomarker. Light-colored powder produced from carefully chosen fresh Amla via a novel process that retains the natural goodness. Self-affirmed GRAS with over a decade of dietary supplement use. Water-soluble with excellent taste profile — suitable for functional beverages. 90-day clinical trial (124 newly-diagnosed diabetics) showed Saberry at 2 g/day surpassed metformin 500 mg for fasting blood sugar reduction (21.8% vs metformin).

Studied Dose 1 g/day or 2 g/day Saberry — both clinically studied. 1 g comparable to metformin 500 mg; 2 g surpassed metformin for blood sugar. Often formulated as 50-100 mg twice daily for general antioxidant use.
Active Compound Proprietary extract of fresh Emblica officinalis (Amla / Indian Gooseberry) fruit — standardized to a minimum of 10% beta-glucogallin (a Gallotannin compound) as the key biomarker. Distinguished from other Amla extracts that use vitamin C or generic tannins as markers. Self-affirmed GRAS. Light-colored powder, water-soluble, good taste profile.

Benefits

21.8% fasting blood sugar reduction at 2 g/day

In a 90-day multicentric randomized open-label trial in 124 newly-diagnosed Type 2 diabetics with dyslipidemia, Saberry at 2 g/day produced 21.8% lowering of fasting blood sugar levels vs 14.6% with 1 g/day dosage. Both doses showed dose-dependent improvement in glucose and lipid metabolism. The 2 g dose surpassed metformin 500 mg/day results.

Supported by Trial 1

Surpassed metformin in head-to-head trial

The three-arm trial compared Saberry 1 g, Saberry 2 g, and metformin 500 mg. While the 1 g Saberry dose compared favorably with metformin, the 2 g dose surpassed metformin results for fasting blood sugar. Note: metformin 500 mg is the low end of therapeutic dosing (typical 1,000-2,000 mg) — comparison limited by this design choice, though still clinically informative.

Supported by Trial 1

Comprehensive lipid profile improvement

Same 90-day trial documented dose-dependent improvements in total cholesterol, LDL, VLDL, and triglyceride levels with Saberry supplementation. The multi-marker lipid improvement addresses metabolic syndrome comprehensively rather than single-parameter intervention. Particularly relevant for diabetic dyslipidemia where lipid management is critical alongside glucose control.

Supported by Trial 1

Post-prandial blood sugar reduction

The clinical trial documented significant improvement in post-prandial blood sugar (PPBS) levels alongside fasting blood sugar. Post-prandial glucose spikes drive much of the cardiovascular and microvascular damage in diabetes. Addressing both fasting and post-meal glucose provides comprehensive glycemic control.

Supported by Trial 1

HbA1c reduction

Saberry supplementation significantly reduced hemoglobin A1c (HbA1c) in the 90-day trial. HbA1c reflects average blood glucose over 2-3 months and is the gold-standard measure of long-term glycemic control. Sustained HbA1c reduction is the key outcome for reducing diabetes complications — vascular damage, retinopathy, neuropathy, nephropathy.

Supported by Trial 1

Beta-glucogallin biomarker standardization

Saberry is the only Amla extract standardized to beta-glucogallin — a Gallotannin compound that holds the key to health benefits obtained from Indian Gooseberry. Distinguished from other Amla products standardized to phenols, generic tannins, or low-molecular-weight hydrolyzable tannins. The specific marker enables reproducible bioactivity.

Supported by Trial 3, Trial 2

Antioxidant and rejuvenative properties

Amla's antioxidant potential has been extensively studied — well-known for rejuvenative properties in traditional Ayurvedic medicine. Helps maintain anti-oxidant enzyme levels in the system. Widely used in digestive support and immune support applications. Traditional use spanning thousands of years in Ayurvedic medicine supports broad safety and tolerability.

Supported by Trial 3

Water-soluble functional beverage applications

Saberry's water-solubility and excellent taste profile make it uniquely suitable for functional beverages, smoothies, and RTD products — distinguished from many botanical extracts limited to capsules/tablets by taste or solubility issues. Self-affirmed GRAS supports formulation flexibility across food and beverage applications.

Supported by Trial 3

Mechanism of action

1

Beta-glucogallin bioactivity

Beta-glucogallin is a Gallotannin compound (gallic acid linked to glucose) with documented antioxidant, anti-inflammatory, and metabolic effects. Saberry's standardization to ≥10% beta-glucogallin ensures reproducible bioactivity. Beta-glucogallin has documented aldose reductase inhibition — relevant for diabetic complication prevention.

2

Aldose reductase inhibition

Aldose reductase converts glucose to sorbitol in the polyol pathway — driving diabetic complications including cataracts, neuropathy, and retinopathy. Beta-glucogallin and other Amla bioactives inhibit aldose reductase, addressing this damaging pathway. Mechanism complements direct glucose-lowering effects.

3

Polyphenol antioxidant activity

Amla contains numerous phytoconstituents — polyphenols, tannins, gallic acid, ellagic acid, amino acids, vitamins, minerals, fixed oils, and flavonoids. The polyphenols, tannins, and flavonoids play key roles in most of E. officinalis bioactivities. Antioxidant activity supports metabolic health alongside the broader anti-aging traditional Ayurvedic positioning.

4

Anti-inflammatory effects

Amla bioactives have documented anti-inflammatory effects across multiple cellular models. Chronic low-grade inflammation drives metabolic syndrome and diabetic complications. Reducing inflammation supports comprehensive metabolic health beyond pure glucose/lipid markers.

5

Antioxidant enzyme upregulation

Amla helps maintain anti-oxidant enzyme levels in the system — supporting endogenous antioxidant defense beyond direct antioxidant scavenging. The mechanism is more physiologically sustainable than single-molecule antioxidant supplementation (which can saturate). Upregulated antioxidant enzymes provide sustained cellular protection.

Clinical trials

1
Saberry vs Metformin — 90-Day Pivotal RCT

90-day multicentric randomized open-label clinical trial comparing two doses of Saberry (1 g and 2 g/day) with metformin 500 mg/day in newly-diagnosed Type 2 diabetics with dyslipidemia. Three-arm design. Outcomes: fasting blood sugar (FBS), post-prandial blood sugar (PPBS), HbA1c, lipid profile, safety parameters. Published in Food & Function (2022;13:9523-31).

124 newly diagnosed Type 2 diabetic subjects aged 30-65 with diabetic dyslipidemia. Three-arm 90-day intervention.

Both Saberry doses produced dose-dependent improvements in glucose and lipid metabolism. 2 g/day produced 21.8% fasting blood sugar reduction vs 14.6% with 1 g/day. 1 g dose compared favorably with metformin; 2 g dose surpassed metformin results. Significant improvements in total cholesterol, LDL, VLDL, triglycerides, HbA1c, and post-prandial blood sugar. Safe and well-tolerated.

2
Saberry Mechanism — Beta-Glucogallin Bioactivity Studies

Preclinical and in vitro mechanistic studies on Saberry's beta-glucogallin bioactivity, including aldose reductase inhibition (relevant for diabetic complications) and antioxidant pathway modulation. Foundation for the human clinical trial findings.

Not applicable — in vitro and preclinical mechanistic studies.

Beta-glucogallin demonstrated aldose reductase inhibition and antioxidant pathway activation. Mechanistic foundation for the clinical glucose-lowering and lipid-improving effects. The standardization to beta-glucogallin (vs generic tannins or vitamin C) is supported by the mechanistic data — beta-glucogallin is the key bioactive driving the metabolic effects.

3
Amla Traditional + Modern Class Evidence

Class evidence for Emblica officinalis (Amla) across traditional Ayurvedic use spanning thousands of years and modern preclinical/clinical research. Amla has been used extensively in digestive support and immune applications. Numerous studies of various Amla extracts for diabetes, cholesterol, and antioxidant outcomes.

Various — adults across traditional Ayurvedic use and modern Amla research base.

Amla consistently demonstrates antioxidant, anti-inflammatory, and metabolic health effects. Long traditional use precedent supports broad safety profile. Saberry's beta-glucogallin standardization distinguishes from other Amla products that may have less reproducible bioactivity. Self-affirmed GRAS supports the safety positioning of standardized extracts.

Side effects and drug interactions

Common Potential side effects

Self-affirmed GRAS status; extensive traditional Ayurvedic use of Amla.
Mild GI effects rare; some individuals report mild stomach upset on empty stomach.
Amla has natural tartness; Saberry has improved taste profile vs raw Amla.
Long-term safety supported by 10+ years of dietary supplement use and Ayurvedic precedent.
Possible mild blood-thinning effect at high doses — relevant before surgery.
Pregnancy and lactation: dietary Amla is safe in moderation; supplemental doses consult clinician.
Water-soluble nature supports broad formulation safety.

Important Drug interactions

Diabetes medications (metformin, sulfonylureas, insulin) — additive glucose-lowering effects; monitor blood glucose; may require dose adjustment of prescription medications.
Anticoagulants (warfarin) — Amla may have mild antiplatelet effects; monitor INR.
Statins and cholesterol medications — possible additive lipid-lowering effects.
Antihypertensive medications — possible mild additive effects.
Iron supplements — Amla is high in vitamin C, may enhance iron absorption; complementary.
Aspirin and NSAIDs — Amla may have mild antiplatelet effects.
Pregnancy and lactation: consult clinician for supplemental doses.

More Metabolic Health Ingredients

Metabolic Health
Psyllium Husk (Plantago ovata)
Psyllium husk is the soluble fiber derived from the seed husks of Plantago ovata — the mos…
Metabolic Health
Thiamine
Thiamine, also known as vitamin B1, is a water-soluble vitamin essential for converting ca…
Metabolic Health
Berberine
Berberine is a bioactive compound extracted from plants like barberry and goldenseal, know…
Metabolic Health
Inositol (Myo-Inositol)
Inositol is a naturally occurring sugar alcohol that acts as a secondary messenger in insu…

Explore Other Ingredients

Metabolic Health
Fenugreek
Fenugreek is an aromatic seed used both as a culinary spice and a supplement, best known f…
Antioxidant
Moringa
Moringa (Moringa oleifera) is a fast-growing tree whose leaves are dried into a nutrient-d…
Immune Support
Spirulina
Spirulina is a blue-green algae celebrated as a nutrient-dense superfood, packed with prot…

Frequently asked questions about Saberry® (Standardized Amla Extract — Sabinsa)

What is Saberry?

Saberry® is Sabinsa's proprietary, patent-pending extract of fresh Indian Gooseberry fruit (Emblica officinalis / Phyllanthus emblica, commonly known as Amla) — the only Amla extract standardized to beta-glucogallin (a Gallotannin compound) as the key biomarker.

What is Saberry used for?

Saberry is researched primarily for Metabolic Health and Antioxidant. In a 90-day multicentric randomized open-label trial in 124 newly-diagnosed Type 2 diabetics with dyslipidemia, Saberry at 2 g/day produced 21.8% lowering of fasting blood sugar levels vs 14.6% with 1 g/day dosage.

What is the recommended dosage of Saberry?

The clinically studied dose is 1 g/day or 2 g/day Saberry — both clinically studied. 1 g comparable to metformin 500 mg; 2 g surpassed metformin for blood sugar. Often formulated as 50-100 mg twice daily for general antioxidant use. Always follow the product label and check with a healthcare provider for personal advice.

Is Saberry safe, and does it have side effects?

For most healthy adults, Saberry is well tolerated at studied doses. Reported effects can include: Self-affirmed GRAS status; extensive traditional Ayurvedic use of Amla. Mild GI effects rare; some individuals report mild stomach upset on empty stomach. It may also interact with some medications. Saberry is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Saberry interact with any medications?

Possible interactions include: Diabetes medications (metformin, sulfonylureas, insulin) — additive glucose-lowering effects; monitor blood glucose; may require dose adjustment of prescription medications. Anticoagulants (warfarin) — Amla may have mild antiplatelet effects; monitor INR. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Saberry?

NutraSmarts rates the evidence for Saberry as Strong (4 out of 5). It is backed by 3 clinical trials and 2 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Kapoor MP, Suzuki K, Derek T, Ozeki M, Okubo T Clinical evaluation of Emblica Officinalis Gatertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study Contemporary Clinical Trials Communications. 2020;17:100499. doi: 10.1016/j.conctc.2019.100499.PubMedUsed to support: Backs the antioxidant and lipid/vascular claims: 500 mg/day amla (Emblica officinalis) over 18 weeks improved blood fluidity, lowered oxidative-stress biomarkers, raised HDL and lowered LDL vs placebo in healthy adults. Honest limits: generic amla extract (not Saberry/beta-glucogallin-specific); a small industry-linked crossover trial with modest effect sizes.
  2. Upadya H, Prabhu S, Prasad A, Subramanian D, Gupta S, Goel A A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia BMC Complementary and Alternative Medicine. 2019;19(1):27. doi: 10.1186/s12906-019-2430-y.PubMedUsed to support: Backs the lipid claim: 12 weeks of standardized Emblica officinalis (amla) extract significantly lowered total cholesterol, triglycerides, LDL and VLDL vs placebo in dyslipidemic patients. Honest limits: generic amla extract rather than Saberry specifically; modest lipid changes from a small industry-sponsored multicenter trial.